Literature DB >> 19190304

A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection.

Ciarán P Kelly1.   

Abstract

Clostridium difficile infection (CDI) is a common and increasingly severe nosocomial infectious disease. The case of Mr S, a 76-year-old man with multiple recurrences of CDI, illustrates the difficulties in treating recurrent disease and the way it complicates the management of other medical conditions. Risk factors for CDI include antimicrobial use, hospital admission, advancing age, and severe underlying disease. A clinical diagnosis of CDI is usually confirmed by identifying C. difficile toxins in a stool sample. Evidence supports metronidazole, 500 mg every 6 hours for 10 to 14 days, as the treatment of choice for mild to moderately severe CDI. Oral vancomycin, 125 mg every 6 hours for 10 to 14 days, is recommended for severe CDI, for which it is more effective than metronidazole. Recurrent CDI occurs in more than 20% of patients when metronidazole or vancomycin treatment is discontinued. Few studies have evaluated treatment options for recurrent CDI, but a prolonged, tapering, and pulse-dosed regimen of oral vancomycin is commonly used. Careful attention to antimicrobial stewardship and infection control practices is essential to curb this nosocomial, iatrogenic disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190304     DOI: 10.1001/jama.2009.171

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  32 in total

1.  Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.

Authors:  Fnu Rafiullah; Sunil Kanwal; Usman M Majeed; Mark A Korsten; Faisal H Cheema; Munish Luthra; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2011-11-21

Review 2.  Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review.

Authors:  Madison M Murphy; Edna Patatanian; Mark A Gales
Journal:  Ther Adv Infect Dis       Date:  2018-09-12

3.  Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease.

Authors:  A N Ananthakrishnan; R Guzman-Perez; V Gainer; T Cai; S Churchill; I Kohane; R M Plenge; S Murphy
Journal:  Aliment Pharmacol Ther       Date:  2012-02-23       Impact factor: 8.171

Review 4.  Antimicrobial drugs.

Authors:  Daniel E Becker
Journal:  Anesth Prog       Date:  2013

5.  Preoperative Clostridium difficile infection is not associated with an increased risk for the infection in ileal pouch patients.

Authors:  Chao Sun; Peng Du; Xian-rui Wu; Elaine Queener; Bo Shen
Journal:  Dig Dis Sci       Date:  2014-02-07       Impact factor: 3.199

6.  Bowel preparation for colectomy and risk of Clostridium difficile infection.

Authors:  Greta L Krapohl; Laurel R S Phillips; Darrell A Campbell; Samantha Hendren; Mousumi Banerjee; Bonnie Metzger; Arden M Morris
Journal:  Dis Colon Rectum       Date:  2011-07       Impact factor: 4.585

7.  The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis.

Authors:  Tara Lagu; Mihaela S Stefan; Sarah Haessler; Thomas L Higgins; Michael B Rothberg; Brian H Nathanson; Nicholas S Hannon; Jay S Steingrub; Peter K Lindenauer
Journal:  J Hosp Med       Date:  2014-04-09       Impact factor: 2.960

Review 8.  Clostridium difficile infection: epidemiology, risk factors and management.

Authors:  Ashwin N Ananthakrishnan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-30       Impact factor: 46.802

Review 9.  Efficacy of cleaning products for C. difficile: environmental strategies to reduce the spread of Clostridium difficile-associated diarrhea in geriatric rehabilitation.

Authors:  Nora Macleod-Glover; Cheryl Sadowski
Journal:  Can Fam Physician       Date:  2010-05       Impact factor: 3.275

10.  Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab.

Authors:  Andrada Seicean; Anca Moldovan-Pop; Radu Seicean
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.